This clinical trial is focused on studying the treatment of tumors of the sinuses and salivary glands. These tumors can be either resected, meaning they have been surgically removed, or non-operable, meaning surgery is not an option. The study involves two treatment approaches: one group will receive radiotherapy alone, while the other group will receive a combination of radiotherapy and a chemotherapy drug called cisplatin. Cisplatin is administered as a solution for infusion, which means it is given through a vein.
The purpose of the study is to compare the effectiveness of these two treatment methods in preventing the progression of the disease. Participants will be randomly assigned to one of the two treatment groups. Throughout the study, participants will receive regular assessments to monitor their health and the progression of their condition. The study aims to determine which treatment approach offers better outcomes in terms of progression-free survival, which refers to the length of time during and after treatment that a patient lives with the disease without it getting worse.
In addition to progression-free survival, the study will also look at other important factors such as overall survival, quality of life, and the time it takes for the disease to progress locally or spread to other parts of the body. The study will also monitor any side effects that participants may experience, particularly those that are severe. The trial is expected to continue until 2030, with recruitment starting in 2024.
Belgium 
France 
